Search
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.
Fencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose.
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalThis allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043]. … It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046].
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigational, and a high level of accumulation in tumors. … Unlike <sup>68</sup>Ga-labeled PSMA-targeting ligands, <sup>18</sup>F-labeled compounds targeting this protein have a longer half-life and can be produced in larger batches.
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedMetrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. … In general, the drug was well tolerated by patients during cardiac examinations [A32091].
Categories: Compounds used in a research, industrial, or household settingMepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnPharmacologically, it is a post-ganglionic parasympathetic inhibitor. … It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalIn patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity is lower. … Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawna 68% reduction in the risk of death were observed. … This approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and